 Stacie Daugherty
Concepts (259)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 12 | 2024 | 1276 | 2.420 |
Why?
| | Out-of-Hospital Cardiac Arrest | 6 | 2024 | 121 | 2.030 |
Why?
| | Healthcare Disparities | 11 | 2021 | 736 | 1.820 |
Why?
| | Sex Factors | 24 | 2026 | 2110 | 1.790 |
Why?
| | Antihypertensive Agents | 8 | 2021 | 521 | 1.770 |
Why?
| | Cardiopulmonary Resuscitation | 6 | 2024 | 339 | 1.630 |
Why?
| | Medication Adherence | 6 | 2026 | 540 | 1.400 |
Why?
| | Exercise Test | 5 | 2017 | 630 | 1.240 |
Why?
| | Myocardial Infarction | 11 | 2017 | 1211 | 1.080 |
Why?
| | Racism | 5 | 2022 | 147 | 1.050 |
Why?
| | Cardiology | 7 | 2024 | 362 | 1.030 |
Why?
| | Cardiovascular Diseases | 8 | 2026 | 2191 | 0.900 |
Why?
| | Registries | 21 | 2026 | 2410 | 0.840 |
Why?
| | Heart Failure | 8 | 2022 | 2326 | 0.790 |
Why?
| | Practice Guidelines as Topic | 4 | 2019 | 1582 | 0.790 |
Why?
| | Coronary Disease | 3 | 2011 | 382 | 0.780 |
Why?
| | Blood Pressure | 5 | 2019 | 1782 | 0.760 |
Why?
| | Social Values | 2 | 2021 | 40 | 0.720 |
Why?
| | Risk Assessment | 7 | 2022 | 3752 | 0.690 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 5 | 2018 | 229 | 0.650 |
Why?
| | Cardiologists | 2 | 2018 | 45 | 0.650 |
Why?
| | Defibrillators, Implantable | 6 | 2019 | 387 | 0.630 |
Why?
| | Multimodal Imaging | 5 | 2024 | 129 | 0.620 |
Why?
| | Sleep Wake Disorders | 2 | 2022 | 314 | 0.600 |
Why?
| | Myocardial Ischemia | 3 | 2022 | 285 | 0.590 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2020 | 85 | 0.590 |
Why?
| | Public Opinion | 1 | 2019 | 62 | 0.560 |
Why?
| | Adrenergic beta-Antagonists | 5 | 2018 | 252 | 0.560 |
Why?
| | Attitude to Health | 1 | 2021 | 430 | 0.550 |
Why?
| | United States | 33 | 2025 | 16126 | 0.550 |
Why?
| | Primary Prevention | 4 | 2015 | 222 | 0.540 |
Why?
| | Death, Sudden, Cardiac | 4 | 2015 | 237 | 0.540 |
Why?
| | Patient Acceptance of Health Care | 1 | 2025 | 883 | 0.540 |
Why?
| | Stroke | 5 | 2026 | 1271 | 0.540 |
Why?
| | Middle Aged | 36 | 2026 | 36309 | 0.540 |
Why?
| | Risk Factors | 19 | 2026 | 10919 | 0.540 |
Why?
| | Radiography, Thoracic | 1 | 2019 | 172 | 0.530 |
Why?
| | Female | 57 | 2026 | 79045 | 0.530 |
Why?
| | Clinical Decision-Making | 2 | 2018 | 364 | 0.510 |
Why?
| | Male | 51 | 2026 | 73010 | 0.510 |
Why?
| | Humans | 72 | 2026 | 145783 | 0.490 |
Why?
| | Thromboembolism | 1 | 2017 | 129 | 0.470 |
Why?
| | Disease Management | 2 | 2019 | 653 | 0.470 |
Why?
| | Anemia | 1 | 2017 | 191 | 0.470 |
Why?
| | Warfarin | 1 | 2017 | 179 | 0.460 |
Why?
| | Hospitalization | 3 | 2025 | 2461 | 0.450 |
Why?
| | Follow-Up Studies | 13 | 2022 | 5428 | 0.450 |
Why?
| | Patient Discharge | 5 | 2022 | 995 | 0.450 |
Why?
| | Hemoglobins | 1 | 2017 | 386 | 0.440 |
Why?
| | Anticoagulants | 2 | 2018 | 748 | 0.440 |
Why?
| | Coronary Artery Disease | 5 | 2022 | 750 | 0.440 |
Why?
| | Ultrasonography | 1 | 2019 | 788 | 0.430 |
Why?
| | Atrial Fibrillation | 2 | 2018 | 558 | 0.420 |
Why?
| | Quality of Health Care | 2 | 2020 | 693 | 0.410 |
Why?
| | Percutaneous Coronary Intervention | 3 | 2017 | 549 | 0.410 |
Why?
| | Aged | 27 | 2026 | 26217 | 0.410 |
Why?
| | American Heart Association | 5 | 2020 | 358 | 0.400 |
Why?
| | Sleep | 2 | 2022 | 889 | 0.400 |
Why?
| | Guideline Adherence | 1 | 2018 | 587 | 0.390 |
Why?
| | Practice Patterns, Physicians' | 3 | 2018 | 1372 | 0.390 |
Why?
| | Sex Distribution | 5 | 2020 | 388 | 0.390 |
Why?
| | Ambulatory Care | 1 | 2018 | 610 | 0.380 |
Why?
| | Hemostasis, Surgical | 1 | 2013 | 25 | 0.380 |
Why?
| | Emergency Service, Hospital | 1 | 2025 | 2383 | 0.370 |
Why?
| | Aged, 80 and over | 11 | 2026 | 8347 | 0.370 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2017 | 444 | 0.370 |
Why?
| | Blood Loss, Surgical | 1 | 2013 | 114 | 0.360 |
Why?
| | Postoperative Hemorrhage | 1 | 2013 | 105 | 0.350 |
Why?
| | Health Status Disparities | 3 | 2021 | 321 | 0.350 |
Why?
| | Drug Resistance | 1 | 2012 | 145 | 0.350 |
Why?
| | Adult | 22 | 2026 | 40881 | 0.300 |
Why?
| | Resuscitation Orders | 2 | 2020 | 48 | 0.290 |
Why?
| | Patient Selection | 2 | 2013 | 739 | 0.290 |
Why?
| | Patient Preference | 1 | 2011 | 223 | 0.280 |
Why?
| | Multivariate Analysis | 4 | 2017 | 1547 | 0.270 |
Why?
| | Electrocardiography | 1 | 2011 | 668 | 0.260 |
Why?
| | Incidence | 7 | 2022 | 2934 | 0.260 |
Why?
| | Societies, Medical | 4 | 2024 | 900 | 0.260 |
Why?
| | Cardiac Catheterization | 1 | 2011 | 559 | 0.250 |
Why?
| | Young Adult | 13 | 2026 | 14254 | 0.250 |
Why?
| | Risk Reduction Behavior | 2 | 2026 | 217 | 0.240 |
Why?
| | Cohort Studies | 7 | 2025 | 6033 | 0.240 |
Why?
| | Aspirin | 2 | 2017 | 406 | 0.240 |
Why?
| | Coronary Angiography | 1 | 2008 | 328 | 0.240 |
Why?
| | Thoracic Surgery | 2 | 2017 | 143 | 0.230 |
Why?
| | Lung | 1 | 2019 | 4116 | 0.230 |
Why?
| | Heart Diseases | 2 | 2019 | 341 | 0.220 |
Why?
| | Continuity of Patient Care | 1 | 2008 | 297 | 0.220 |
Why?
| | Retrospective Studies | 14 | 2024 | 17330 | 0.220 |
Why?
| | Heart Arrest | 2 | 2020 | 411 | 0.210 |
Why?
| | Heart-Assist Devices | 2 | 2022 | 568 | 0.210 |
Why?
| | Insurance, Health | 2 | 2025 | 311 | 0.210 |
Why?
| | Touch Perception | 1 | 2024 | 17 | 0.200 |
Why?
| | Secondary Prevention | 2 | 2017 | 251 | 0.200 |
Why?
| | Health Knowledge, Attitudes, Practice | 3 | 2024 | 1420 | 0.200 |
Why?
| | Text Messaging | 1 | 2026 | 182 | 0.190 |
Why?
| | Housing | 1 | 2024 | 142 | 0.190 |
Why?
| | Prospective Studies | 7 | 2019 | 8078 | 0.190 |
Why?
| | Odds Ratio | 5 | 2017 | 1083 | 0.190 |
Why?
| | Migraine Disorders | 1 | 2024 | 114 | 0.180 |
Why?
| | Prognosis | 6 | 2019 | 4330 | 0.180 |
Why?
| | Intention to Treat Analysis | 1 | 2021 | 79 | 0.170 |
Why?
| | Treatment Outcome | 11 | 2026 | 11794 | 0.170 |
Why?
| | Women's Health | 2 | 2016 | 316 | 0.170 |
Why?
| | Peptide Fragments | 2 | 2017 | 697 | 0.170 |
Why?
| | Colorado | 4 | 2026 | 4556 | 0.170 |
Why?
| | Single-Blind Method | 1 | 2021 | 318 | 0.160 |
Why?
| | Self Report | 2 | 2022 | 876 | 0.160 |
Why?
| | Hospital Mortality | 4 | 2018 | 1038 | 0.160 |
Why?
| | Professional-Patient Relations | 1 | 2021 | 147 | 0.160 |
Why?
| | Writing | 1 | 2021 | 101 | 0.160 |
Why?
| | Telephone | 1 | 2021 | 177 | 0.160 |
Why?
| | Alaska Natives | 1 | 2021 | 97 | 0.150 |
Why?
| | Health Behavior | 1 | 2026 | 791 | 0.150 |
Why?
| | Drug Therapy, Combination | 2 | 2019 | 1043 | 0.150 |
Why?
| | Sex Characteristics | 5 | 2022 | 789 | 0.150 |
Why?
| | Sexuality | 1 | 2019 | 32 | 0.140 |
Why?
| | Cardiac Resynchronization Therapy Devices | 1 | 2019 | 18 | 0.140 |
Why?
| | Survival Rate | 5 | 2020 | 2094 | 0.140 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2019 | 56 | 0.140 |
Why?
| | Electric Countershock | 1 | 2019 | 126 | 0.140 |
Why?
| | Clinical Audit | 1 | 2018 | 14 | 0.140 |
Why?
| | Congresses as Topic | 1 | 2020 | 224 | 0.140 |
Why?
| | Ventricular Function | 1 | 2018 | 53 | 0.140 |
Why?
| | Prevalence | 3 | 2024 | 2875 | 0.140 |
Why?
| | Heart Failure, Diastolic | 1 | 2018 | 23 | 0.140 |
Why?
| | Heart Failure, Systolic | 1 | 2018 | 26 | 0.130 |
Why?
| | Logistic Models | 4 | 2012 | 2139 | 0.130 |
Why?
| | Atherosclerosis | 1 | 2022 | 409 | 0.130 |
Why?
| | Time Factors | 6 | 2018 | 7134 | 0.130 |
Why?
| | Predictive Value of Tests | 3 | 2019 | 2123 | 0.130 |
Why?
| | F Factor | 1 | 2017 | 4 | 0.130 |
Why?
| | Postmenopause | 1 | 2020 | 394 | 0.130 |
Why?
| | Residence Characteristics | 1 | 2020 | 375 | 0.130 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 2 | 2017 | 38 | 0.130 |
Why?
| | Ezetimibe | 1 | 2017 | 24 | 0.130 |
Why?
| | Patient Readmission | 2 | 2020 | 773 | 0.130 |
Why?
| | Positron-Emission Tomography | 1 | 2019 | 343 | 0.130 |
Why?
| | Health Care Surveys | 1 | 2019 | 536 | 0.130 |
Why?
| | Transgender Persons | 1 | 2020 | 210 | 0.130 |
Why?
| | Simvastatin | 1 | 2017 | 59 | 0.130 |
Why?
| | Point-of-Care Systems | 1 | 2019 | 189 | 0.120 |
Why?
| | Poverty | 1 | 2020 | 529 | 0.120 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2017 | 109 | 0.120 |
Why?
| | Chi-Square Distribution | 1 | 2017 | 528 | 0.120 |
Why?
| | Indians, North American | 1 | 2021 | 598 | 0.120 |
Why?
| | Heart Valve Diseases | 1 | 2017 | 151 | 0.120 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2017 | 103 | 0.120 |
Why?
| | Sex Offenses | 1 | 2019 | 196 | 0.120 |
Why?
| | Blood Pressure Determination | 2 | 2014 | 145 | 0.110 |
Why?
| | Mortality | 2 | 2008 | 381 | 0.110 |
Why?
| | Anticholesteremic Agents | 1 | 2017 | 155 | 0.110 |
Why?
| | Diagnostic Imaging | 1 | 2017 | 337 | 0.110 |
Why?
| | Anesthesiology | 1 | 2017 | 179 | 0.110 |
Why?
| | Waiting Lists | 1 | 2017 | 266 | 0.110 |
Why?
| | Administration, Oral | 1 | 2017 | 867 | 0.110 |
Why?
| | Aortic Valve Stenosis | 1 | 2017 | 256 | 0.110 |
Why?
| | Ambulatory Care Facilities | 2 | 2020 | 269 | 0.100 |
Why?
| | Communication | 2 | 2018 | 977 | 0.100 |
Why?
| | Angiography | 3 | 2020 | 208 | 0.100 |
Why?
| | Acute Coronary Syndrome | 1 | 2017 | 297 | 0.100 |
Why?
| | Hirudins | 1 | 2013 | 53 | 0.090 |
Why?
| | Decision Support Techniques | 1 | 2017 | 480 | 0.090 |
Why?
| | Antithrombins | 1 | 2013 | 71 | 0.090 |
Why?
| | Obesity | 2 | 2024 | 3118 | 0.090 |
Why?
| | Medicaid | 1 | 2017 | 467 | 0.090 |
Why?
| | Heart Defects, Congenital | 1 | 2020 | 910 | 0.090 |
Why?
| | Referral and Consultation | 1 | 2019 | 869 | 0.090 |
Why?
| | Diuretics | 1 | 2012 | 68 | 0.090 |
Why?
| | Critical Care | 1 | 2018 | 702 | 0.090 |
Why?
| | Hemorrhage | 1 | 2017 | 822 | 0.090 |
Why?
| | Depression | 1 | 2021 | 1559 | 0.090 |
Why?
| | Echocardiography | 3 | 2020 | 648 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2013 | 2028 | 0.080 |
Why?
| | Health Personnel | 1 | 2018 | 757 | 0.080 |
Why?
| | Adolescent | 8 | 2026 | 22577 | 0.080 |
Why?
| | Heart Transplantation | 1 | 2017 | 680 | 0.080 |
Why?
| | Stroke Volume | 1 | 2013 | 655 | 0.080 |
Why?
| | Recombinant Proteins | 1 | 2013 | 1368 | 0.080 |
Why?
| | Aftercare | 2 | 2022 | 222 | 0.070 |
Why?
| | Age Factors | 4 | 2022 | 3346 | 0.070 |
Why?
| | Biomarkers | 2 | 2017 | 4302 | 0.070 |
Why?
| | Hospitals | 1 | 2014 | 733 | 0.070 |
Why?
| | Eligibility Determination | 1 | 2009 | 72 | 0.070 |
Why?
| | Medicare | 3 | 2022 | 904 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 4 | 2020 | 2770 | 0.070 |
Why?
| | Poisson Distribution | 1 | 2008 | 78 | 0.070 |
Why?
| | Proportional Hazards Models | 2 | 2008 | 1330 | 0.070 |
Why?
| | Pregnancy | 1 | 2020 | 7216 | 0.060 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 5925 | 0.060 |
Why?
| | Magnetic Resonance Imaging, Cine | 2 | 2017 | 214 | 0.060 |
Why?
| | Regression Analysis | 1 | 2008 | 1001 | 0.060 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2026 | 133 | 0.060 |
Why?
| | Veterans | 1 | 2017 | 1642 | 0.050 |
Why?
| | Longitudinal Studies | 1 | 2012 | 2968 | 0.050 |
Why?
| | Heart Rate | 1 | 2008 | 856 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2026 | 413 | 0.050 |
Why?
| | Recovery of Function | 1 | 2008 | 716 | 0.050 |
Why?
| | Evidence-Based Medicine | 1 | 2008 | 740 | 0.050 |
Why?
| | Primary Health Care | 1 | 2014 | 1737 | 0.050 |
Why?
| | Pilot Projects | 2 | 2020 | 1898 | 0.040 |
Why?
| | Surgical Procedures, Operative | 1 | 2024 | 271 | 0.040 |
Why?
| | Alaska | 1 | 2021 | 77 | 0.040 |
Why?
| | Cholesterol | 1 | 2022 | 408 | 0.040 |
Why?
| | Databases, Factual | 1 | 2026 | 1491 | 0.040 |
Why?
| | Gender Identity | 1 | 2020 | 129 | 0.040 |
Why?
| | Age Distribution | 1 | 2020 | 404 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2024 | 6085 | 0.040 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2014 | 2602 | 0.040 |
Why?
| | Perception | 1 | 2021 | 378 | 0.030 |
Why?
| | Minority Health | 1 | 2018 | 18 | 0.030 |
Why?
| | SEER Program | 1 | 2019 | 230 | 0.030 |
Why?
| | Hospitals, Rural | 1 | 2018 | 49 | 0.030 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2020 | 627 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2026 | 2933 | 0.030 |
Why?
| | Hospitals, Urban | 1 | 2018 | 142 | 0.030 |
Why?
| | California | 1 | 2019 | 473 | 0.030 |
Why?
| | Advisory Committees | 1 | 2019 | 229 | 0.030 |
Why?
| | Risk Adjustment | 1 | 2017 | 85 | 0.030 |
Why?
| | Europe | 1 | 2017 | 421 | 0.030 |
Why?
| | Consensus | 1 | 2019 | 479 | 0.030 |
Why?
| | Exercise | 1 | 2008 | 2205 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2024 | 3634 | 0.030 |
Why?
| | Prosthesis Design | 1 | 2018 | 356 | 0.030 |
Why?
| | Medically Uninsured | 1 | 2017 | 132 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2009 | 2977 | 0.030 |
Why?
| | Needs Assessment | 1 | 2019 | 403 | 0.030 |
Why?
| | Veterans Health | 1 | 2017 | 190 | 0.030 |
Why?
| | Body Mass Index | 1 | 2024 | 2447 | 0.030 |
Why?
| | Insurance Coverage | 1 | 2017 | 244 | 0.030 |
Why?
| | Frail Elderly | 1 | 2015 | 136 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 849 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1378 | 0.030 |
Why?
| | Radial Artery | 1 | 2014 | 75 | 0.030 |
Why?
| | Liver Cirrhosis | 1 | 2015 | 288 | 0.020 |
Why?
| | Caregivers | 1 | 2022 | 1074 | 0.020 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 588 | 0.020 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2017 | 499 | 0.020 |
Why?
| | United States Department of Veterans Affairs | 1 | 2017 | 779 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1662 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 1062 | 0.020 |
Why?
| | Cholesterol, LDL | 1 | 2014 | 360 | 0.020 |
Why?
| | Intensive Care Units | 1 | 2018 | 924 | 0.020 |
Why?
| | Dementia | 1 | 2015 | 328 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3418 | 0.020 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2014 | 303 | 0.020 |
Why?
| | Qualitative Research | 1 | 2018 | 1683 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2018 | 1197 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2014 | 1327 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2015 | 668 | 0.020 |
Why?
| | Obstetrics | 1 | 2011 | 177 | 0.020 |
Why?
| | Gynecology | 1 | 2011 | 181 | 0.020 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 920 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2015 | 1101 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 3916 | 0.010 |
Why?
| | Cause of Death | 1 | 2008 | 472 | 0.010 |
Why?
| | Insulin | 1 | 2014 | 2516 | 0.010 |
Why?
| | Child | 1 | 2020 | 22740 | 0.010 |
Why?
| | Neoplasms | 1 | 2015 | 2913 | 0.010 |
Why?
|
|
Daugherty's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|